- Home
- OPT vs PLL Comparison
OPT vs PLL Comparison
Compare OPT & PLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PLL
- Stock Information
- Founded
- OPT 1984
- PLL 2016
- Country
- OPT Australia
- PLL United States
- Employees
- OPT N/A
- PLL N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PLL Other Metals and Minerals
- Sector
- OPT Health Care
- PLL Basic Materials
- Exchange
- OPT Nasdaq
- PLL Nasdaq
- Market Cap
- OPT 201.5M
- PLL 217.1M
- IPO Year
- OPT 2020
- PLL 2017
- Fundamental
- Price
- OPT $2.92
- PLL $6.68
- Analyst Decision
- OPT Strong Buy
- PLL Buy
- Analyst Count
- OPT 2
- PLL 8
- Target Price
- OPT $14.00
- PLL $25.47
- AVG Volume (30 Days)
- OPT 11.2K
- PLL 528.8K
- Earning Date
- OPT 08-30-2024
- PLL 11-04-2024
- Dividend Yield
- OPT N/A
- PLL N/A
- EPS Growth
- OPT N/A
- PLL N/A
- EPS
- OPT N/A
- PLL N/A
- Revenue
- OPT $261,859.00
- PLL $66,444,999.00
- Revenue This Year
- OPT N/A
- PLL $191.01
- Revenue Next Year
- OPT $55,563.16
- PLL $4.80
- P/E Ratio
- OPT N/A
- PLL N/A
- Revenue Growth
- OPT N/A
- PLL N/A
- 52 Week Low
- OPT $1.60
- PLL $6.58
- 52 Week High
- OPT $4.40
- PLL $46.33
- Technical
- Relative Strength Index (RSI)
- OPT 61.45
- PLL 35.29
- Support Level
- OPT $2.84
- PLL $7.40
- Resistance Level
- OPT $3.14
- PLL $8.11
- Average True Range (ATR)
- OPT 0.14
- PLL 0.68
- MACD
- OPT -0.00
- PLL -0.06
- Stochastic Oscillator
- OPT 52.54
- PLL 3.59
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.